Pharmaceutical and Healthcare Industry in Brazil - Forecast and Analysis 2021

Pharmaceutical and Healthcare Industry in Brazil - Forecast and Analysis 2021

  • August 2021 •
  • 140 pages •
  • Report ID: 6130542 •
  • Format: PDF
Brazil has been one of the worst COVID-affected countries in the world. The Brazilian government has been severely criticized for its handling of the pandemic. In March 2021, Brazilians began receiving the first dose of the vaccine.

The pharmaceutical and healthcare market in Brazil is the biggest in Latin America. The Brazilian pharmaceutical market is also one of the most attractive markets in the Americas regions. With a high burden of diseases, the pharmaceutical sector in the country is poised for fast growth despite the pandemic. The industry is dominated by generic products.

Though there will be some short-term impacts felt on the market from the COVID-19 pandemic, the expenditure on healthcare and pharmaceuticals will continue to increase in the coming years. With many changes and a new business strategy in place, the Brazilian healthcare industry is today one of the most attractive globally, drawing investments from all over the world.

Aruvian Research presents an in-depth analysis of the Pharmaceutical and Healthcare Industry of Brazil in its research report Pharmaceutical and Healthcare Industry in Brazil – Forecast and Analysis 2021. The report covers the following data:

• A brief overview of the pharmaceutical and healthcare industry in the Americas and a snapshot of the sector across some leading and underperforming markets of the region.

• An in-depth coverage of the pharmaceutical and healthcare industry in Brazil by sectors along with an analysis of how the COVID-19 pandemic is effecting the industry.

• We analyze the segments of prescription drugs, generic drugs, OTC medicines, and also analyze the landscape for medical research and clinical trials in Brazil.

• A SWOT analysis of the Brazilian pharmaceutical and healthcare industry.

• A Porter’s Five Forces Strategic Analysis of the Brazilian pharmaceutical and healthcare Industry is included that looks at the bargaining power of buyers and suppliers, competitive rivalry in the industry, and the threat of new entrants and industry substitution.

• We take an up-close view of the regulatory framework governing the Brazilian pharmaceutical and healthcare industry, and the challenges being faced in terms of intellectual property rights.

• Competition in the industry, along with an in-depth analysis of the both the domestic and multinational players in the sector like Aché, Cristália, Eurofarma, EMS, Medley, GlaxoSmithKline, Roche, Sanofi, and many others is included.

A detailed forecast of the Brazilian pharmaceutical and healthcare industry by segments completes this comprehensive analysis.
Loading...

We are very sorry, but an error occurred.
Please contact [email protected] if the problem remains.